SCHEMBL29015454

SCHEMBL29015454

COC(=O)C1Cc2c(Cl)cc(F)c(Cl)c2N1

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 3/20 0.38
KDM4E B2RXH2 2/20 0.38
HSD17B10 Q99714 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
GAA P10253 1/20 0.38
CYP2D6 P10635 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
CYP2C19 P33261 1/20 0.38
TSHR P16473 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7653260 0.74 PDE5A (0.41) PDE5AKDM4EHSD17B10ALDH1A1CYP1A2
SCHEMBL8326659 0.72 KDM4E (0.45) PDE5AKDM4EHSD17B10ALDH1A1CYP1A2
SCHEMBL5567865 0.69 PDE5A (0.39) PDE5AGAAMAPT
SCHEMBL5568857 0.69 PDE5A (0.43) PDE5AKDM4EHSD17B10ALDH1A1CYP1A2
SCHEMBL22697206 0.69 GAA (0.39) KDM4EHSD17B10ALDH1A1CYP1A2GAA
SCHEMBL5568366 0.69 KDM4E (0.42) PDE5AKDM4EHSD17B10ALDH1A1CYP1A2
SCHEMBL5917429 0.67 PDE5A (0.44) PDE5AGAAMAPT
SCHEMBL16879027 0.65 KDM4E (0.44) KDM4EHSD17B10ALDH1A1CYP1A2GAA
SCHEMBL16879026 0.65 KDM4E (0.44) KDM4EHSD17B10ALDH1A1CYP1A2GAA
SCHEMBL8787725 0.64 PDE5A (0.38) PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116096714-A Antiviral compounds for the treatment of coronavirus, picornavirus and norovirus infections 安力高医药股份有限公司 2023-05-09 CN disclosed
EP-4165037-A1 ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS Aligos Therapeutics, Inc. (US) 2023-04-19 EP disclosed